Humira (Abbott Laboratories)

Humira (Abbott Laboratories) - General Information

Anti-TNF antibody, expressed in mammalian cell culture, 1330 residues, MW=148 kD. Humira was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl:K constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system


Pharmacology of Humira (Abbott Laboratories)

Used in the treatment of rheumatoid arthritis. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the disease. Humira (Abbott Laboratories) binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting the joint destruction.


Humira (Abbott Laboratories) for patients


Humira (Abbott Laboratories) Interactions


HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX. The data do not suggest the need for dose adjustment of either HUMIRA or MTX.


Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone. The safety and efficacy of anakinra used in combination with HUMIRA has not been studied. Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.


Humira (Abbott Laboratories) Contraindications

HUMIRA should not be administered to patients with known hypersensitivity to HUMIRA or any of its components.


Additional information about Humira (Abbott Laboratories)

Humira (Abbott Laboratories) Indication: For treatment of rheumatoid arthritis
Mechanism Of Action: Humira (Abbott Laboratories) binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Humira (Abbott Laboratories) also lyses surface TNF expressing cells in vitro in the presence of complement.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Adalimumab
Synonyms: Ig gamma-1 chain C region
Drug Category: Antirheumatic Agents; Immunomodulatory Agents
Drug Type: Biotech; Approved

Other Brand Names containing Adalimumab: Humira (Abbott Laboratories);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system.
Half Life: 10-20 days.
Dosage Forms of Humira (Abbott Laboratories): Solution Subcutaneous
Chemical IUPAC Name: Humanized anti-TNF antibody (D2E7)
Chemical Formula: C6428H9912N1694O1987S46
Adalimumab on Wikipedia:
Organisms Affected: Humans and other mammals